Abstract
Fifty-nine outpatients with insomnia were treated in a 3-week study to assess the safety and efficacy of a new triazolothienodiazepine with a short t 1 2, brotizolam. Therapy was initiated with 0.25 mg at night, but by the end of the study all subjects who were receiving brotizolam were taking 0.50 mg. Results indicate brotizolam efficacy as measured by daily subject and weekly physician questionnaires in essentially all sleep parameters, including global subject and physician evaluation of treatment efficacy, sleep latency and sleep maintenance, and quality of sleep. Tolerance to the hypnotic action of brotizolam was not observed after 21 days of daily dosing.
| Original language | English |
|---|---|
| Pages (from-to) | 674-679 |
| Number of pages | 6 |
| Journal | Clinical Pharmacology and Therapeutics |
| Volume | 37 |
| Issue number | 6 |
| State | Published - Jun 1 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Hypnotic efficacy of a modified triazolodiazepine, brotizolam. / Dominguez, Roberto A.; Goldstein, Burton J.; Jacobson, Alan F.; Steinbook, Richard M.
In: Clinical Pharmacology and Therapeutics, Vol. 37, No. 6, 01.06.1985, p. 674-679.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hypnotic efficacy of a modified triazolodiazepine, brotizolam
AU - Dominguez, Roberto A.
AU - Goldstein, Burton J.
AU - Jacobson, Alan F.
AU - Steinbook, Richard M.
PY - 1985/6/1
Y1 - 1985/6/1
N2 - Fifty-nine outpatients with insomnia were treated in a 3-week study to assess the safety and efficacy of a new triazolothienodiazepine with a short t 1 2, brotizolam. Therapy was initiated with 0.25 mg at night, but by the end of the study all subjects who were receiving brotizolam were taking 0.50 mg. Results indicate brotizolam efficacy as measured by daily subject and weekly physician questionnaires in essentially all sleep parameters, including global subject and physician evaluation of treatment efficacy, sleep latency and sleep maintenance, and quality of sleep. Tolerance to the hypnotic action of brotizolam was not observed after 21 days of daily dosing.
AB - Fifty-nine outpatients with insomnia were treated in a 3-week study to assess the safety and efficacy of a new triazolothienodiazepine with a short t 1 2, brotizolam. Therapy was initiated with 0.25 mg at night, but by the end of the study all subjects who were receiving brotizolam were taking 0.50 mg. Results indicate brotizolam efficacy as measured by daily subject and weekly physician questionnaires in essentially all sleep parameters, including global subject and physician evaluation of treatment efficacy, sleep latency and sleep maintenance, and quality of sleep. Tolerance to the hypnotic action of brotizolam was not observed after 21 days of daily dosing.
UR - http://www.scopus.com/inward/record.url?scp=0021864091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021864091&partnerID=8YFLogxK
M3 - Article
C2 - 3891191
AN - SCOPUS:0021864091
VL - 37
SP - 674
EP - 679
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 6
ER -